Report Overview

United States Anticoagulation Therapy Market is flourishing owing to the rising incidence of venous thromboembolism, atrial fibrillation, and stroke, long-term administration as well a high volume of recurring anticoagulation drug sales along with the rising demand for novel oral anticoagulants (NOACs)...

United States Anticoagulation Therapy Market - Industry Trends & Forecast Report 2028

United States Anticoagulation Therapy Market was worth USD 23.15 billion in 2021 and is further projected to reach USD 39.43 billion by the year 2028, exhibiting a CAGR of 7.9% during the forecast period (2022-2028). The rapid expansion of the market is predominantly due to cardiovascular diseases and venous thromboembolism (VTE) is becoming more common. Also, novel oral anticoagulants (NOACs) are being used more often, and knowledge of NOACs is growing in developing nations. Moreover, the growing older population and surge in demand for innovative therapies are both predicted to fuel market expansion. Furthermore, the market for anticoagulation clinics is expanding as a result of the rising incidence of blood disorders, high levels of drug adherence linked to clinics, and an aging population. 

Anticoagulation Therapy - Overview

Anticoagulant drugs are also known as blood thinners. These are chemical substances that prevent or reduce blood coagulation and lengthen the time it takes for blood to clot. These medications are primarily used in patients with a high risk of blood clots in conditions such as atrial fibrillation, deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke, and others. Coumarins and indandiones, factor Xa inhibitors, heparins, and direct thrombin inhibitors are the four basic categories into which anticoagulants can be subdivided.

United States Anticoagulation Therapy Market Forecast and Trends

Growth Drivers

Blood Thinner Innovation and Increased Awareness

The rise in cardiovascular health awareness and the ensuing increase in novel pharmaceutical releases are two major factors influencing the growth of the US market. Blood-thinning drugs are a crucial part of that therapy regimen. Cardiovascular therapeutics encompasses a multifaceted strategy that may result in the prescription of numerous different types of medications. Several significant market leaders have launched various anticoagulants, addressing the urgent treatment requirements concerning blood clot prevention.

Rising Chronic Diseases and Technological Advancements

Rapid urbanization is thought to be a contributing factor to an increase in chronic disease cases and technological advancements in anticoagulant product innovation. Ischemic heart disease has increased and is expected to increase rapidly by 2030. However, the rising prevalence of chronic diseases, people's unhealthy lifestyle choices, and the growing shift to novel oral anticoagulants (NOACs) are the major driving forces in the anticoagulants market. Furthermore, technological advancements in anticoagulant medicine innovation are expected to propel the market.

Surging Demand for Novel Treatments

The market for anticoagulant medications has a lot to gain from the growing use of novel oral anticoagulants (NOACs) and growing awareness of NOACs in developing countries. The market is expected to develop as a result of both the rising elderly population and the surge in demand for novel treatments. Additionally, novel pharmaceuticals are substances that differ from any drug product that has previously received approval from the United States Food and Drug Administration (FDA), also known as new molecular entities or new compounds. These medications are cutting-edge goods that provide a fresh approach to addressing specific medical ailments. Moreover, venous thromboembolism (VTE) and cardiovascular problems are becoming more common, which has created a promising growth opportunity for the industry.

Restraints

Stringent Regulatory Guidelines

During the projected period, market size is anticipated to be constrained by strict regulatory requirements and an elevated risk of treatment-related side effects. The market for anticoagulant products is being constrained by rising health awareness of adverse effects such as Malena, hemoptysis, epistaxis, menorrhagia, hematuria, and bleeding gums. The rising cost of the medications is creating a challenge for the expansion of the industry along with improvements in technology and anticoagulant quality. All these factors restrain the growth of the United States Anticoagulation Market.

Impact of COVID-19 on United States Anticoagulation Therapy Market

Because of the increasing pace of research, the COVID-19 pandemic is expected to have a significant impact on the anticoagulant industry. Clinical trials are currently underway to assess the efficacy of anticoagulants in COVID-19 patients. As a result, the COVID-19 pandemic will have both direct and indirect implications for the market. Furthermore, according to a World Health Organization update issued in January 2021, patients infected with COVID-19, both suspected and confirmed, must be provided with the follow-up care that includes a low dose of anticoagulants. As a result, the demand for anticoagulants increased during the pandemic and is likely to rise during the forecast period (2022-2028).

United States Anticoagulation Therapy Market - By Product Type

Based on the product type, the United States Anticoagulation Therapy Market is segmented into Drugs (Novel Oral Anticoagulants (NOAC’s), Warfarin (VKA)), PT/INR Testing Devices (In-Office Testing Devices, Analyzers, Reagents and Kits, Home Testing Devices), Service (Testing Services and Consulting Services). Among these, drugs comprising novel oral anticoagulants (NOAC’s) account to hold the largest market share. Because NOACs are safer and more effective than traditional therapies, they are being used more frequently. Additionally, key market participants such as Portola Pharmaceuticals (which received FDA approval for its NOAC Betrixaban in July 2017) are focusing on NOAC development to capitalize on the growth opportunities presented by this shift in market dynamics. As a result, many other companies are expected to focus on developing safer and more efficient NOACs in the coming years, ensuring the segment's continued growth.

Furthermore, among PT/INR Testing Devices, the United States Anticoagulation Therapy Market dominates the in-office devices segment. The high percentage of patients choosing in-office testing services is primarily responsible for the segment's size. However, because of its benefits, including convenience, time and money savings, and speedy result generation, the home testing devices category is anticipated to develop at the greatest CAGR. Furthermore, exams and test-related expenses are frequently reimbursable.

United States Anticoagulation Therapy Market – By Clinic

Based on the clinic, the United States Anticoagulation Therapy Market is segmented into Hospital Associated Clinic, Independent Clinics, and Pharmacy-Based Clinics. Among these, the pharmacy-based clinic segment holds the largest market share. The number of anticoagulation clinics situated in pharmacies has considerably expanded in the US during the past few years. This is because therapy managed by knowledgeable pharmacists rather than care delivered by family physicians yields superior results. The market for pharmacy-based anticoagulation clinics is anticipated to grow as a result of the lower cost of therapy offered by these clinics compared to independent and hospital-affiliated anticoagulation clinics.

Competitive Landscape

The leading market players in the United States Anticoagulation Therapy Market are Bristol-Myers Squibb, Johnson & Johnson, Pfizer, Portola Pharmaceuticals, C.H. Boehringer Sohn, Daiichi Sankyo, Abbott, Siemens, Roche, Alere, and other prominent players.

The United States Anticoagulation Therapy Market is highly fragmented with the presence of several manufacturing companies in the country. The market leaders retain their supremacy by spending on research and development, incorporating cutting-edge technology into their goods, and releasing upgraded items for customers. Various tactics, including strategic alliances, agreements, mergers, and partnerships, are used.

Scope of the Report

By Product Type

• Drugs

1. Novel Oral Anticoagulants (NOACs)
2. Warfarin (VKA)

• PT/INR Testing Devices

1. In-Office Testing Devices
2. Analyzers
3. Reagents and Kits
4. Home Testing Devices

• Service

1. Testing Services
2. Consulting Services

By Clinic

• Hospital Associated Clinic
• Independent Clinics
• Pharmacy-Based Clinics